Expert consensus on the detection and clinical application of tumor mutational burden.

Cancer Biol Med · 2026 · PMC12980037 · PMID 41704094

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, the efficacy of TMB-guided monoclonal antibodies is limited, because nivolumab monotherapy showed a trend toward improved outcomes in patients with TMB-H, whereas no significant benefit was observed in patients with TMB-L.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.